Received Jan 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | CM9A5 | — |
experienced jaw pain the day after he received the Arexvy vaccine; This non-serious case was reported by a consumer via call center representative and described the occurrence of jaw pain in a 87-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number CM9A5) for prophylaxis. On 08-JAN-2026, the patient received Arexvy. On 09-JAN-2026, 1 days after receiving Arexvy, the patient experienced jaw pain (Verbatim: experienced jaw pain the day after he received the Arexvy vaccine). The outcome of the jaw pain was not resolved. It was unknown if the reporter considered the jaw pain to be related to Arexvy. It was unknown if the company considered the jaw pain to be related to Arexvy.